Navigation Links
Case Western Reserve wins $12.7 million for AIDS research and clinical trials
Date:1/22/2014

AIDS researchers from Case Western Reserve University and University Hospitals Case Medical Center have received a seven-year funding award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

This award includes $12.7 million for core research funding and the potential of an additional $9 million to support clinical trials of promising treatments. This award marks the fifth time the Case Western Reserve University (CWRU)/University Hospitals (UH) AIDS Clinical Trials Unit has received NIAID funding since it began operating in 1987.

"We are very proud to have received this competitive award," said co-principal investigator Michael Lederman, MD, the Scott R. Inkley Professor of Medicine and associate director of the Center for AIDS Research at Case Western Reserve School of Medicine and infectious disease specialist at UH Case Medical Center. "It shows a level of confidence in our unit that encourages and inspires us."

Benigno Rodriguez, MD, co-principal investigator and associate professor of medicine at Case Western Reserve School of Medicine and infectious disease physician at UH Case Medical Center, agreed.

"This award will not only allow us to continue our studies of treatment strategies," he said "It assures we can maintain the outstanding team that has made all this success possible."

The CWRU/UH AIDS Clinical Trials Unit is one of 37 worldwide that will conduct human studies to advance knowledge of the mechanisms of HIV-related diseases, the prevention of HIV acquisition, and the treatment of HIV/AIDS and its complications.

In addition, Cleveland's unit is one of only two U.S. centers funded as study sites for three different research networks clinical treatment trials and prevention trials using microbicides and promising HIV vaccines. (The other center is at the University of California, San Francisco.)

The federal grant enables ongoing research on HIV and AIDS at Case Western Reserve School of Medicine. It also supports clinical research efforts at UH Case Medical Center, the Joint Clinical Research Center in Kampala, Uganda and the University of Cincinnati, a new member which joined the CWRU/UH consortium in 2013.

Cleveland's three-trial testing designation is based on the success of its past funding and research initiatives. The fact that researchers in this area have raised more than $195 million in grants since 2000 has helped to solidify CWRU's place as a global leader in AIDS research and it will continue to provide resources to the city to support local HIV prevention and treatment. Lederman, Rodriguez and other unit researchers are active and recognized worldwide for their research and treatment protocols. This success-breeds-success scenario has produced a supportive Greater Cleveland community with many volunteers who are willing to participate in trials as they become available.

For this year's award, the growing emphasis is on developing more effective methods to prevent HIV infection. The CWRU/UH AIDS Clinical Trials Unit is a part of one HIV treatment network (the AIDS Clinical Trials Group) and two HIV prevention networks: the Microbicide Trials Network and the HIV Vaccine Trials Network. Microbicides are locally administered compounds in the form of a gel, foam or cream that could interrupt the sexual transmission of HIV. The CWRU/UH team, in collaboration with investigators in Geneva, Switzerland and across the U.S., has pioneered a novel approach that entails blocking a component of the human cell membrane that is necessary for almost all strains of sexually-transmitted HIV to gain a foothold inside the body. Human studies are expected to begin this year.

The development of an effective vaccine to reduce HIV transmission has proven elusive so far. But the unit has been chosen to become one of 10 U.S. sites in the vaccine network, in large part because of its proven ability to attract uninfected participants to enroll in vaccine trials and its extensive expertise in HIV immunology. This new designation means that for the next seven years the CWRU/UH AIDS Clinical Trials Unit will offer HIV prevention vaccine trials on a consistent basis in Cleveland.

Despite the life-saving effects of antiviral therapy, some HIV-infected patients experience an increased risk of illnesses related to inflammation. During the new award period, the CWRU/UH AIDS Clinical Trials Unit will extend the scope of its research and conduct new trials aimed at interrupting the persistence of inflammation and developing strategies that target the elimination of HIV infection with the goal of cure.

The award comes with some hefty expectations. "Research conducted in the AIDS Clinical Trials Group network has so altered the course of HIV infection, that many treated patients can now achieve a normal life expectancy," said Lederman. "But many challenges remain for people with HIV-infection." Among them are the continuing stigma associated with the virus, helping patients adhere to daily treatment regimens, and other quality of life issues including an increased risk of heart, kidney and liver diseases and cancer.

Developing more effective methods to prevent HIV infection and fine-tuning treatments to see longer and better lives for patients remain a priority of the 37 clinical trial units, Rodriguez added.


'/>"/>

Contact: Jessica Studeny
jessica.studeny@case.edu
216-368-4692
Case Western Reserve University
Source:Eurekalert

Related biology news :

1. Mesquite trees displacing Southwestern grasslands
2. Study finds Western diet detrimental to fetal hippocampal tissue transplants
3. Grants add to Northwestern-Qatar partnership
4. NASA satellite sees several western US fires blazing
5. UCSB scientists compile first study of potential for tsunamis in northwestern California
6. Team discovers how western corn rootworm resists crop rotation
7. Northwestern scientists create chemical brain
8. Western aspen trees commonly carry extra set of chromosomes
9. Tracking invasive cheatgrass role in larger, more frequent Western fires
10. Wildfires light up western Australia
11. UT Southwestern scientists make mouse model of human cancer, demonstrate cure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
(Date:3/17/2016)... 2016 ABI Research, the leader in ... biometrics market will reach more than $30 billion ... 2015. Consumer electronics, particularly smartphones, continue to boost ... to reach two billion shipments by 2021 at ... , Research Analyst at ABI Research. "Surveillance is ...
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... ( http://www.apimages.com ) - Germany . The ... refugee identity cards. DERMALOG will be unveiling this device, and a ... next week.   --> Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ...
Breaking Biology News(10 mins):
(Date:4/29/2016)... ... April 30, 2016 , ... The MIT bioLogic design team has ... team explored how bacterial properties can be applied to fabric and formed into living ... move in response to humidity change. The team harvested Natto cells and applied them ...
(Date:4/29/2016)... , April 29, 2016 ... Transparency Market Research "Separation Systems for Commercial Biotechnology ... Trends, and Forecast 2015 - 2023", the separation ... US$ 10,665.5 Mn in 2014 and is projected ... 2015 to 2023 to reach US$ 19,227.8 Mn ...
(Date:4/29/2016)... ... ... Intelligent Implant Systems announced today that the two-level components for the Revolution™ Spinal System ... These components expand the capabilities of the system and allow Revolution™ to be utilized ... the company has seen significant sales growth in 1Q 2016, and the system is ...
(Date:4/28/2016)... , April 28, 2016 ... reports the Company,s CEO  was featured in an ... Enter When VCs Fear To Tread: http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001 ... magazine is an essential business journal ... from emerging biotechs to Big Pharmas. Their content ...
Breaking Biology Technology: